Answers are grounded in this paper and cite their sources.
Our newly defined biomarker signature may serve as a complement for current clinical risk stratification approaches and provide potential therapeutic targets for reversing the fibroblast-mediated immunosuppressive microenvironment.
No takes yet. Share an insight, caveat, or question.
He et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: